A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis
British Journal of Haematology · 2025-02 · 206 (2) · 416-427
DOI: 10.1111/bjh.19925 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Haematology, online erschienen am 09.12.2024. Verfasst von Tamanna Haque und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Clonal Hematopoiesis, Clinical Trials as Topic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
The age‐associated mutational state of clonal haematopoiesis (CH) is linked to multiple adverse health outcomes. As higher risk CH can lead to progressive neoplastic or vascular disease, there is interest in developing clinical trials to mitigate risk associated with CH. Given the high prevalence of CH, data from clinical trials could have broad public health implications for screening and therapy. Thoughtful consideration is needed to design trials that are both clinically relevant and avoid overmedicalization. Here, we summarize clinical studies of CH to date and provide suggestions and guidance on how to approach designing CH‐focused therapeutic clinical trials. These recommendations are derived from discussions among clinical researchers and scientists emanating from the Inaugural Meeting on Somatic Mutations and Predisease in October 2021.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Division of Hematologic Malignancies, Department of Oncology, Montefiore-Einstein Comprehensive Cancer Center, Bronx, New York, USA.
- Department of Medicine, Hematology/Oncology, Cornell University, New York, New York, USA.
- Malignant Hematology Department, Moffit Cancer Center, Tampa, Florida, USA.
- Department of Leukemia, MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Medicine, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
ORCID-Profile: Tamanna Haque, Ashwin Kishtagari, Yazan F Madanat, David P Steensma, Michael R Savona
Förderung
- NCI NIH HHS
Zitieren
APA
Haque, T., Shastri, A., Desai, P., Xie, Z., Hammond, D., King, Z., Kishtagari, A., Madanat, Y. F., Abaza, Y., Silver, A. J., Singh, A., Borate, U. M., Heimlich, J. B., Slosky, D. A., Bolton, K. L., Patnaik, M. S., Bick, A. G., Verma, A. K., Jaiswal, S., …, & Savona, M. R. (2025). A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis. British Journal of Haematology, 206(2), 416-427. https://doi.org/10.1111/bjh.19925
Vancouver
Haque T, Shastri A, Desai P, Xie Z, Hammond D, King Z, et al. A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis. British Journal of Haematology. 2025;206(2):416-427. doi:10.1111/bjh.19925
BibTeX
@article{Haque2025,
author = {Haque, Tamanna and Shastri, Aditi and Desai, Pinkal and Xie, Zhuoer and Hammond, Danielle and King, Zoe and Kishtagari, Ashwin and Madanat, Yazan F and Abaza, Yasmin and Silver, Alexander J and Singh, Abhay and Borate, Uma M and Heimlich, J Brett and Slosky, David A and Bolton, Kelly L and Patnaik, Mrinal S and Bick, Alexander G and Verma, Amit K and Jaiswal, Siddhartha and Steensma, David P and Savona, Michael R},
title = {A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis},
journal = {British Journal of Haematology},
year = {2025},
volume = {206},
number = {2},
pages = {416--427},
doi = {10.1111/bjh.19925}
}
EUVIMED